Dasatinib, verteporfin and fluvasatin, all the three YAP1 inhibitors targeting via different mechanisms effectively reduced viability in EGFR-dependent lung adenocarcinoma cells. This evidence concerns the gene EGFR and lung adenocarcinoma.